IP Library Granted Patent US 11,033,604
Granted Patent B2
US 11,033,604 · App. 16/258,505 · Granted Jun 15, 2021

Reagents and methods for treating bacterial infection

Inventors: Valerie Daggett (Seattle, WA); Alissa Bleem (Seattle, WA)
Assignee: University of Washington
A61K38/16A61K9/70A61K38/02A61L27/22A61L27/34A61L27/54A61L29/085A61L29/16A61L31/10A61L31/16A61P31/04A61P41/00A61L2202/24A61L2300/25A61L2300/252A61L2300/404A61L2300/606A61L2420/02C07K16/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,604
App. No.
16/258,505
Granted
Jun 15, 2021
Kind
B2
Abstract

Disclosed herein are α-sheet peptides and their use for treating a bacterial infection and/or limiting bacterial biofilm formation.

Claims (65)

1. A method for treating a bacterial infection, comprising administering to a subject with a bacterial infection an amount of an α-sheet peptide effective to treat the bacterial infection.

2. The method of claim 1 , wherein the bacterial infection comprises a bacterial biofilm, and wherein the treating comprises disruption of the biofilm.

3. The method of claim 1 , wherein the bacterial infection comprises an Escherichia coli , a Pseudomonas aeruginosa , or a Staphylococcus aureus bacterial infection.

4. The method of claim 1 , wherein the bacterial infection comprises a drug or multi-drug resistant bacterial infection.

5. The method of claim 1 , wherein the bacterial infection is contracted during hospitalization.

6. The method of claim 1 , wherein the a-sheet peptide comprises a peptide selected from the group consisting of:

AP90

SEQ ID NO: 1

RGEmNlSwMNEYSGWtMnLkMGR;

AP401

SEQ ID NO: 2

rGeMnLsWmneysGwTmNlKmGr;

AP407

SEQ ID NO: 3

RGEmNlCwMNEYSGWcMnLkMGR;

AP193

SEQ ID NO: 4

RGEmNyFwMNEYYGWtMnCkMGR;

and

AP5

SEQ ID NO: 8

RGNwNeSkMNEYSGWmLmLtMGR;

wherein residues in lower-case are D amino acids, residues in upper case are L amino acids, and G residues are achiral.

7. A method for limiting development of bacterial biofilm, comprising administering to a subject at risk of a bacterial infection comprising biofilm formation with an amount of an α-sheet peptide effective to limit development of the bacterial biofilm, wherein the subject is undergoing a surgical procedure.

8. The method of claim 7 , wherein the surgical procedure comprises placement of a medical device in the subject.

9. The method of claim 8 , wherein the medical device is selected from the group consisting of prosthetic heart valves, cardiac pacemakers, cerebrospinal fluid shunts, urinary catheters, intravascular catheters, ocular prostheses, prosthetic joints, orthopedic implants, titanium-containing implants, polystyrene-containing implants, and intrauterine contraceptive devices.

10. The method of claim 9 , wherein the a-sheet peptide is placed on the medical device prior to placement of the medical device in the subject.

11. The method of claim 7 , wherein the α-sheet peptide comprises a peptide selected from the group consisting of:

AP90

SEQ ID NO: 1

RGEmNlSwMNEYSGWtMnLkMGR;

AP401

SEQ ID NO: 2

rGeMnLsWmneysGwTmNlKmGr;

AP407

SEQ ID NO: 3

RGEmNlCwMNEYSGWcMnLkMGR;

AP193

SEQ ID NO: 4

RGEmNyFwMNEYYGWtMnCkMGR;

and

AP5

SEQ ID NO: 8

RGNwNeSkMNEYSGWmLmLtMGR;

wherein residues in lower-case are D amino acids, residues in upper case are L amino acids and G residues are achiral.

12. A medical device comprising one or more a-sheet peptides coated on a surface of the medical device.

13. The medical device of claim 12 , the medical device is selected from the group consisting of prosthetic heart valves, cardiac pacemakers, cerebrospinal fluid shunts, urinary catheters, intravascular catheters, ocular prostheses, prosthetic joints, orthopedic implants, titanium-containing implants, polystyrene-containing implants, and intrauterine contraceptive devices.

14. The medical device of claim 12 , wherein the a-sheet peptide comprises a peptide selected from the group consisting of:

AP90

(SEQ ID NO: 1)

RGEmNlSwMNEYSGWtMnLkMGR;

AP401

(SEQ ID NO: 2)

rGeMnLsWmneysGwTmNlKmGr;

AP407

(SEQ ID NO: 3)

RGEmNlCwMNEYSGWcMnLkMGR;

AP193

(SEQ ID NO: 4)

RGEmNyFwMNEYYGWtMnCkMGR;

and

AP5

(SEQ ID NO: 8)

RGNwNeSkMNEYSGWmLmLtMGR;

wherein residues in lower-case are D amino acids, residues in upper case are L amino acids, and G residues are achiral.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2019
From: DAGGETT, VALERIE; BLEEM, ALISSA
To: UNIVERSITY OF WASHINGTON
Reel/Frame 048356/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2019
From: DAGGETT, VALERIE; BLEEM, ALISSA
To: UNIVERSITY OF WASHINGTON
Reel/Frame 048302/0457 →
CONFIRMATORY LICENSE Recorded Feb 1, 2019
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048229/0577 →
Continuity (2)
Provisional Application 62622722 · Jan 26, 2018
Related Publication 20190231845A1 · Aug 1, 2019
Cited By (1)
US 12,247,050